<DOC>
	<DOCNO>NCT02454842</DOCNO>
	<brief_summary>This phase 2 study design evaluate safety activity TH-4000 ( Tarloxotinib ) , hypoxia-activated prodrug , patient EGFR-Mutant , T790M-Negative , Advanced non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Study Treatment Patients With EGFR Mutant , T790M-negative NSCLC</brief_title>
	<detailed_description>A single arm open label multi-center Phase 2 study pharmacokinetics , safety , tolerability efficacy TH-4000 ( Tarloxotinib ) assess patient EGFR mutant , T790M negative advance NSCLC . Patients must demonstrate progression EGFR TKI therapy . Hypoxia PET scan obtain select center analyze potential predictor tumor response .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Key Eligibility Criteria : Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Confirmed recurrent Stage IV NSCLC progress treatment EGFR TKI Measurable disease accord Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST 1.1 ) Documented evidence EGFR mutation know associated EGFR TKI sensitivity No T790M mutation small cell transformation include assessment tumor biopsy obtain subsequent recent EGFR TKI therapy Acceptable laboratory result indicate protocol Acceptable cardiac function indicate protocol Key Receiving medication prolongs QT interval , risk cause Torsades de Pointes ( TdP ) unless ECG meet inclusion criterion stable dose medication Family history long QTc syndrome Symptomatic central nervous system ( CNS ) lesion Radiation therapy within 2 week prior first dose study medication Major surgery within 4 week minor surgery within 2 week prior first dose study medication Concurrent active malignancy require systemic treatment Any serious uncontrolled medical disorder psychological condition may interfere study conduct include limited : clinically significant active infection ( e.g. , tuberculosis , viral hepatitis , human immunodeficiency virus [ HIV ] ) , recent ( within 6 month ) myocardial infarction unstable angina , congestive heart failure , poorlycontrolled hypertension diabetes , concurrent active malignancy , psychiatric condition may interfere patient 's ability follow study procedure Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>TH-4000</keyword>
	<keyword>low-oxygen condition</keyword>
	<keyword>hypoxia</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>squamous cell carcinoma</keyword>
	<keyword>Tarloxotinib</keyword>
</DOC>